プロトロンビナーゼ
出典: フリー百科事典『ウィキペディア（Wikipedia）』 (2023/03/05 04:51 UTC 版)
プロトロンビナーゼ（英: prothrombinase）複合体は、セリンプロテアーゼである第Xa因子（活性化第X因子）と、タンパク質コファクター（補因子）である第Va因子（活性化第V因子）から構成される。負に帯電したリン脂質膜上でカルシウムイオン存在下で組み立てられる。プロトロンビナーゼ複合体は、不活性な酵素前駆体であるプロトロンビン（第II因子）から活性型セリンプロテアーゼであるトロンビン（第IIa因子）への変換を触媒する。トロンビンの活性化は、血液凝固カスケードの重要反応である。トロンビンの産生のために、プロトロンビナーゼ複合体はプロトロンビンの2か所のペプチド結合（アルギニン271番残基（Arg271）の直後とArg320の直後）を切断する[1]。第Xa因子はプロトロンビナーゼ複合体と関係していない場合でもプロトロンビンを活性化することが示されているが、トロンビン形成の速度は大きく低下する。プロトロンビナーゼ複合体は第Xa因子単独の場合の30万倍の速度でプロトロンビンの活性化を触媒する[2]。そのため、効率的なトロンビン産生と適切な止血反応にはプロトロンビナーゼ複合体が必要である。
- ^ a b Krishnaswamy S (January 2005). “Exosite-driven substrate specificity and function in coagulation”. J. Thromb. Haemost. 3 (1): 54–67. doi:10.1111/j.1538-7836.2004.01021.x. PMID 15634266.
- ^ a b “The contribution of bovine Factor V and Factor Va to the activity of prothrombinase”. J. Biol. Chem. 254 (21): 10952–62. (November 1979). PMID 500617.
- ^ “Activation of human factor IX (Christmas factor)”. J. Clin. Invest. 61 (6): 1528–38. (June 1978). doi:10.1172/JCI109073. PMC 372679. PMID 659613.
- ^ “The molecular basis of blood coagulation”. Cell 53 (4): 505–18. (May 1988). doi:10.1016/0092-8674(88)90567-3. PMID 3286010.
- ^ “A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S”. Biochemistry 16 (4): 698–706. (February 1977). doi:10.1021/bi00623a022. PMID 836809.
- ^ “A cell-based model of hemostasis”. Thromb. Haemost. 85 (6): 958–65. (June 2001). doi:10.1055/s-0037-1615947. PMID 11434702.
- ^ “Complete cDNA and derived amino acid sequence of human factor V”. Proc. Natl. Acad. Sci. U.S.A. 84 (14): 4846–50. (July 1987). doi:10.1073/pnas.84.14.4846. PMC 305202. PMID 3110773.
- ^ “Factor V: a combination of Dr Jekyll and Mr Hyde”. Blood 101 (1): 20–30. (January 2003). doi:10.1182/blood-2002-01-0290. PMID 12393635.
- ^ a b c “Cofactor proteins in the assembly and expression of blood clotting enzyme complexes”. Annu. Rev. Biochem. 57: 915–56. (1988). doi:10.1146/annurev.bi.57.070188.004411. PMID 3052293.
- ^ a b c Krishnaswamy S (March 1990). “Prothrombinase complex assembly. Contributions of protein-protein and protein-membrane interactions toward complex formation”. J. Biol. Chem. 265 (7): 3708–18. PMID 2303476.
- ^ “The phosphatidylserine binding site of the factor Va C2 domain accounts for membrane binding but does not contribute to the assembly or activity of a human factor Xa-factor Va complex”. Biochemistry 44 (2): 711–8. (January 2005). doi:10.1021/bi047962t. PMID 15641797.
- ^ “Proposed structural models of the prothrombinase (FXa-FVa) complex”. Proteins 63 (3): 440–50. (May 2006). doi:10.1002/prot.20848. PMID 16437549.
- ^ “The prothrombinase-catalyzed activation of prothrombin proceeds through the intermediate meizothrombin in an ordered, sequential reaction”. J. Biol. Chem. 261 (19): 8977–84. (July 1986). PMID 3755135.
- ^ “The role of phospholipids and factor Va in the prothrombinase complex”. J. Biol. Chem. 255 (1): 274–83. (January 1980). PMID 7350159.
- ^ “Kinetic studies of prothrombin activation: effect of factor Va and phospholipids on the formation of the enzyme-substrate complex”. Biochemistry 23 (20): 4557–64. (September 1984). doi:10.1021/bi00315a008. PMID 6498156.
- ^ “Purification and properties of prothrombin activator from the venom of Echis carinatus”. J. Biochem. 83 (2): 559–70. (February 1978). PMID 416016.
- ^ a b “The conversion of prothrombin to thrombin. III. The factor Xa-catalyzed activation of prothrombin”. J. Biol. Chem. 249 (24): 7782–90. (December 1974). PMID 4430674.
- ^ “Activation of human prothrombin by human prothrombinase. Influence of factor Va on the reaction mechanism”. J. Biol. Chem. 262 (7): 3291–9. (March 1987). PMID 3818642.
- ^ “Loss of prothrombin and of factor Xa-factor Va interactions upon inactivation of factor Va by activated protein C”. J. Biol. Chem. 259 (22): 13986–92. (November 1984). PMID 6438088.
- ^ “The binding of activated protein C to factors V and Va”. J. Biol. Chem. 261 (21): 9684–93. (July 1986). PMID 3755431.
- ^ “Studies of the capacity of factor Xa to protect factor Va from inactivation by activated protein C”. J. Biol. Chem. 257 (3): 1443–7. (February 1982). PMID 6895752.
- ^ “Five novel mutations in the gene for human blood coagulation factor V associated with type I factor V deficiency”. Blood 98 (2): 358–67. (July 2001). doi:10.1182/blood.V98.2.358. PMID 11435304.
- ^ Auerswald G (2006). “Prophylaxis in rare coagulation disorders -- factor X deficiency”. Thromb. Res. 118 Suppl 1: S29–31. doi:10.1016/j.thromres.2006.01.015. PMID 16574201.
- ^ “The mechanism of inactivation of human factor V and human factor Va by activated protein C”. J. Biol. Chem. 269 (50): 31869–80. (December 1994). PMID 7989361.
- ^ “Activated protein C resistance and factor V Leiden: a review”. Arch. Pathol. Lab. Med. 131 (6): 866–71. (June 2007). doi:10.1043/1543-2165(2007)131[866:APCRAF]2.0.CO;2. PMID 17550313.
- ^ “Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study)”. Thromb. Haemost. 77 (3): 444–51. (March 1997). PMID 9065991.
- ^ a b “Cardiology patient page. Factor V Leiden”. Circulation 107 (15): e94–7. (April 2003). doi:10.1161/01.CIR.0000068167.08920.F1. PMID 12707252.
- ^ “A prospective study of venous thromboembolism in relation to factor V Leiden and related factors”. Blood 99 (8): 2720–5. (April 2002). doi:10.1182/blood.V99.8.2720. PMID 11929758.
- ^ “The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies”. Haematologica 92 (8): 1107–14. (August 2007). doi:10.3324/haematol.10234. PMID 17650440.
- ^ “Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement”. J. Biol. Chem. 267 (18): 12528–38. (June 1992). PMID 1618758.
- ^ Bauer KA (December 2003). “New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology”. Chest 124 (6 Suppl): 364S–370S. doi:10.1378/chest.124.6_suppl.364S. PMID 14668419.
- ^ “New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism”. Vasc Health Risk Manag 1 (1): 41–53. (2005). doi:10.2147/vhrm.1.1.41.58936. PMC 1993925. PMID 17319097.
- ^ Kearon C (August 2004). “Long-term management of patients after venous thromboembolism”. Circulation 110 (9 Suppl 1): I10–8. doi:10.1161/01.CIR.0000140902.46296.ae. PMID 15339876.
- ^ “Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor”. J. Med. Chem. 48 (19): 5900–8. (September 2005). doi:10.1021/jm050101d. PMID 16161994.
- ^ a b “Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa”. J. Med. Chem. 50 (22): 5339–56. (November 2007). doi:10.1021/jm070245n. PMID 17914785.
- ^ “Structure-based design of novel potent nonpeptide thrombin inhibitors”. J. Med. Chem. 45 (9): 1757–66. (April 2002). doi:10.1021/jm0109513. PMID 11960487.
- ^ “In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor”. J. Thromb. Haemost. 3 (3): 514–21. (March 2005). doi:10.1111/j.1538-7836.2005.01166.x. PMID 15748242.
- ^ “New anticoagulants for treatment of venous thromboembolism”. Arterioscler. Thromb. Vasc. Biol. 28 (3): 380–6. (March 2008). doi:10.1161/ATVBAHA.108.162677. PMID 18296593.
[続きの解説]
「プロトロンビナーゼ」の続きの解説一覧
- 1 プロトロンビナーゼとは
- 2 プロトロンビナーゼの概要
- 3 不活性化
- 4 出典
- プロトロンビナーゼのページへのリンク
